Skip to Content

Bausch & Lomb Corp BLCO

Morningstar Rating
CAD 19.95 +0.29 (1.48%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

BLCO is trading at a 43% discount.
Price
CAD 19.66
Fair Value
CAD 54.30
Uncertainty
High
1-Star Price
CAD 33.47
5-Star Price
CAD 32.80
Economic Moat
Bywjylz
Capital Allocation
Stxgyjj

Bulls Say, Bears Say

Bulls

As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company.

Bears

Bausch will face margin pressures from upcoming losses of exclusivity on its pharmaceuticals, and this might hinder its efforts to raise margins to a level comparable with that of its close competitors.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLCO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CAD 19.66
Day Range
CAD 19.78–19.95
52-Week Range
CAD 18.41–28.96
Bid/Ask
CAD 19.92 / CAD 19.97
Market Cap
CAD 7.00 Bil
Volume/Avg
1,000 / 3,913

Key Statistics

Price/Earnings (Normalized)
18.71
Price/Sales
1.23
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
13,300

Competitors

Valuation

Metric
BLCO
AFX
COO
Price/Earnings (Normalized)
18.7130.4727.19
Price/Book Value
0.764.042.33
Price/Sales
1.234.174.92
Price/Cash Flow
18.9023.1820.88
Price/Earnings
BLCO
AFX
COO

Financial Strength

Metric
BLCO
AFX
COO
Quick Ratio
0.742.410.81
Current Ratio
1.743.401.86
Interest Coverage
0.3622.054.77
Quick Ratio
BLCO
AFX
COO

Profitability

Metric
BLCO
AFX
COO
Return on Assets (Normalized)
2.15%—2.49%
Return on Equity (Normalized)
3.72%—3.88%
Return on Invested Capital (Normalized)
4.42%—3.63%
Return on Assets
BLCO
AFX
COO
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncBzxwpbftSgcv$132.1 Bil
BDX
Becton Dickinson & CoWpbqlzyKnxcb$67.4 Bil
ALC
Alcon IncDshngytyhGzqnqpw$39.1 Bil
CLPBY
Coloplast A/S ADRXqpqxpjbwTsyq$28.8 Bil
WST
West Pharmaceutical Services IncKsjytjgmpYzmz$27.6 Bil
RMD
ResMed IncNvkbcypjjbDzfglt$26.1 Bil
BAX
Baxter International IncPvjtkgfFlsxgk$20.1 Bil
COO
The Cooper Companies IncHypwlfkdQqylpm$18.0 Bil
HOLX
Hologic IncDmcwyptssYqqntqv$17.6 Bil
TFX
Teleflex IncYrybHskwl$9.8 Bil

Sponsor Center